Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427091 | 1.00 | LPL (0.41) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL30385846 | 0.86 | LPL (0.40) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL20508307 | 0.86 | LPL (0.40) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL24630498 | 0.84 | LPL (0.46) | LPLLIPGJAK2BTKCA12 | |
| SCHEMBL28147238 | 0.83 | EGFR (0.39) | LPLLIPGEGFRCA12CA1 | |
| SCHEMBL15551341 | 0.83 | LPL (0.38) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL4872385 | 0.83 | MPL (0.39) | LPLLIPGJAK2BTKKDM4E | |
| SCHEMBL2026497 | 0.83 | LPL (0.38) | LPLLIPGJAK2BTK | |
| SCHEMBL28530415 | 0.83 | LPL (0.38) | LPLLIPGJAK2BTK | |
| SCHEMBL30237979 | 0.82 | CA1 (0.44) | LPLLIPGEGFRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619101-A1 | NOVEL PYRROLO[1,2-d][1,2,4]TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS | Neurosterix Pharma Sàrl (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2025-02-25 | — | — | US | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024105018-A1 | NOVEL PYRROLO[1,2-d][1,2,4]TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS | ADDEX PHARMA S.A. (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2022-11-17 | — | — | US | disclosed |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2022-08-16 | — | — | US | disclosed |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | US | disclosed |
| US-20150175623-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-06-25 | — | — | US | disclosed |
| EP-2886545-A1 | New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2015-06-24 | — | — | EP | disclosed |
| US-20150133471-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2015-05-14 | — | — | US | disclosed |
| US-8865911-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2014-10-21 | — | — | US | disclosed |
| WO-2014150809-A1 | NOVEL 4-AMINOPYRIDINE AND 6-AMINOPYRIMIDINE CARBOXYLATES AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2655378-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | AstraZeneca AB (SE) | 2013-10-30 | — | — | EP | disclosed |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133471-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | LPL 1307/4885LIPG 578/4885EGFR 1390/4885 |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | LPL 1307/4885LIPG 578/4885EGFR 1390/4885 |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | BACE1, BACE2, APP | LPL 1307/4885LIPG 578/4885EGFR 1390/4885 |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM2 | LPL 2749/4885LIPG 2860/4885EGFR 1531/4885 |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | LPL 2749/4885LIPG 2860/4885EGFR 1531/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | LPL 2/4885LIPG 23/4885EGFR 1870/4885 |
| US-20150175623-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | LPL 4515/4885LIPG 4399/4885EGFR 3460/4885 |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | LPL 2/4885LIPG 23/4885EGFR 1843/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | LPL 2/4885LIPG 23/4885EGFR 1843/4885 |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM3 | LPL 3669/4885LIPG 3516/4885EGFR 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.